Zoledronate for Osteopenia in Pediatric Crohn's

• This study is recruiting 40 children and adolescents, aged 6 to 18, who have a proven abnormal bone density as measured on a special type of x-ray called a DEXA-scan.
• Participants are allocated at random to one of two groups: either treatment with zoledronate, or a placebo.
• Neither the participants or the physicians are aware of which group each participant is in.
• Participants are followed every three months for one year, and assessed with blood tests, urine tests, physical examination, diet questionnaire and exercise questionnaire.
• Participants have a repeat DEXA scan at 6 and 12 months after beginning the study.
• Once all participants are enrolled and followed for one whole year, we will compare the bone density of the group treated with zoledronate with the group treated with placebo.

Inclusion criteria

• patients aged 6 to 18,
• diagnosed with Crohn's disease with osteopenia,
• a minimum of 6 months of adequate calcium and vitamin D intake. (Osteopenia was defined for the purposes of this study as: Z-score lumber spine BMD by DEXA of -2.0 or less, or -1.5 and a risk factor (either steroid use for 6 months or more or decrease of 0.5 z-score in the preceding 12 months).)

Exclusion criteria

• renal dysfunction,
• insufficient calcium or vitamin D intake,
• current medication or condition affecting bone metabolism,
• documented fracture, previously diagnosed bone disease,
• documented intolerance/hypersensitivity to bisphosphonates,
• previous treatment with bisphosphonates within the last 6 months.